Development of a novel anti-inflammatory nanoparticle for the treatment of Acute Lung Injury

开发用于治疗急性肺损伤的新型抗炎纳米颗粒

• 批准号: MR/J014680/1
• 负责人: Christopher Scott
• 金额: $ 67.67万
• 依托单位: Queen's University Belfast
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2012
• 资助国家: 英国
• 起止时间: 2012 至 无数据
• 项目状态: 已结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FJ014680%2F1
• 关键词: Development; novel; anti; inflammatory; nanoparticle

Acute lung injury is a life threatening and incapacitating condition that affects 20% of all critically ill patients in intensive care. Around 30-50% of these sufferers will die from the condition and many survivors can have serious reductions in the quality of the life with chronic lung problems. This not only has a major effect on the patients themselves, but is also a serious resource allocation problem for the NHS as an ICU bed costs in excess of £1800 per day. There is no effective treatments for this condition at this time and therefore new medicines are urgently needed that can deal and stabilise the condition. ALI is characterised by a vicious cycle of inflammation in the lung that leads to inappropriate infiltration of immune cells to the lung. We have developed a potential treatment for this condition that may have the ability to be nasally delivered to patients in intensive care that has potent anti-inflammatory effects. This treatment is a nano-sized formulation that binds specifically to immunosuppressive receptors found on the surface of immune cells such as macrophages, resulting in significant reduction of the production of inflammatory signaling molecules called cytokines. Therefore in this proposal we aim to bring this treatment closer to clinical development by evaluating its effectiveness in a range of preclinical models of ALI. This work will inform us on its effectiveness, side effects and formulation and dosing of the therapeutic required to obtain a significant effect.

急性肺损伤是一种危及生命和致残的疾病，影响20%的重症监护患者。大约30-50%的患者会死于这种疾病，许多幸存者的生活质量会因慢性肺部问题而严重下降。这不仅对患者本身有重大影响，而且对NHS来说也是一个严重的资源分配问题，因为ICU床位每天的成本超过1800英镑。目前还没有有效的治疗方法，因此迫切需要新的药物来处理和稳定病情。ALI的特征是肺部炎症的恶性循环，导致免疫细胞不适当地浸润到肺部。我们已经开发出一种潜在的治疗这种疾病的方法，可能有能力通过鼻腔输送给重症监护患者，具有强效抗炎作用。这种治疗是一种纳米尺寸的制剂，它特异性地结合免疫细胞表面上发现的免疫抑制受体，如巨噬细胞，从而显著减少称为细胞因子的炎症信号分子的产生。因此，在本提案中，我们的目标是通过评估其在一系列ALI临床前模型中的有效性，使这种治疗更接近临床开发。这项工作将告知我们其有效性，副作用以及获得显着效果所需的治疗制剂和剂量。